Cronos Group (TSX:CRON) FCF Margin % : 62.82% (As of Dec. 2023)

View and export this data going back to 2014. Start your Free Trial

What is Cronos Group FCF Margin %?

FCF Margin % is calculated as Free Cash Flow divided by its Revenue. Cronos Group's Free Cash Flow for the three months ended in Dec. 2023 was C$20.2 Mil. Cronos Group's Revenue for the three months ended in Dec. 2023 was C$32.1 Mil. Therefore, Cronos Group's FCF Margin % for the quarter that ended in Dec. 2023 was 62.82%.

As of today, Cronos Group's current FCF Yield % is -4.09%.

The historical rank and industry rank for Cronos Group's FCF Margin % or its related term are showing as below:

TSX:CRON' s FCF Margin % Range Over the Past 10 Years
Min: -1443.27 Med: -551.13 Max: -53.02
Current: -53.34

During the past 10 years, the highest FCF Margin % of Cronos Group was -53.02%. The lowest was -1443.27%. And the median was -551.13%.

TSX:CRON's FCF Margin % is ranked worse than
84.78% of 1025 companies
in the Drug Manufacturers industry
Industry Median: -0.68 vs TSX:CRON: -53.34

Cronos Group FCF Margin % Historical Data

The historical data trend for Cronos Group's FCF Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Cronos Group FCF Margin % Chart

Cronos Group Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

FCF Margin %

Get a 7-Day Free Trial

-716.41

-385.84

-256.93

-108.34

-53.02

Cronos Group Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
FCF Margin %	Get a 7-Day Free Trial															-114.10	-240.75	-64.54	-2.05	62.82

Competitive Comparison of Cronos Group's FCF Margin %

For the Drug Manufacturers - Specialty & Generic subindustry, Cronos Group's FCF Margin %, along with its competitors' market caps and FCF Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Cronos Group's FCF Margin % Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Cronos Group's FCF Margin % distribution charts can be found below:

* The bar in red indicates where Cronos Group's FCF Margin % falls into.

Cronos Group FCF Margin % Calculation

FCF margin is the ratio of Free Cash Flow divided by net sales or Revenue, usually presented in percent.

Cronos Group's FCF Margin for the fiscal year that ended in Dec. 2023 is calculated as

FCF Margin	=	Free Cash Flow (A: Dec. 2023 )	/	Revenue (A: Dec. 2023 )
	=	-62.059	/	117.043
	=	-53.02 %

Cronos Group's FCF Margin for the quarter that ended in Dec. 2023 is calculated as

FCF Margin	=	Free Cash Flow (Q: Dec. 2023 )	/	Revenue (Q: Dec. 2023 )
	=	20.155	/	32.084
	=	62.82 %

Cronos Group FCF Margin % Related Terms

Thank you for viewing the detailed overview of Cronos Group's FCF Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.

Cronos Group (TSX:CRON) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Cronos Group Inc (TSX:CRON) » Definitions » FCF Margin %

Comparable Companies

Traded in Other Exchanges

CRON:USA 7CI:Germany

Address

111 Peter Street, Suite 300, Toronto, ON, CAN, M5V 2H1

Website

https://www.thecronosgroup.com

Cronos Group, headquartered in Toronto, Canada cultivates and sells medicinal and recreational cannabis through its medicinal brand, Peace Naturals, and its two recreational brands, Cove and Spinach. Although it primarily operates in Canada, Cronos exports medical cannabis primarily to Israel. In the U.S. the company has an option to acquire 10.5% of U.S. multistate operator PharmaCann upon easing of federal prohibition.